These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37959261)

  • 1. Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease.
    Wong R; Qin L; Pan Y; Mahtani P; Longman R; Lukin D; Scherl E; Battat R
    J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis.
    Yarur AJ; Jain A; Hauenstein SI; Quintero MA; Barkin JS; Deshpande AR; Sussman DA; Singh S; Abreu MT
    Inflamm Bowel Dis; 2016 Feb; 22(2):409-15. PubMed ID: 26752470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
    Roblin X; Marotte H; Rinaudo M; Del Tedesco E; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):80-84.e2. PubMed ID: 23891927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
    Peyrin-Biroulet L; Loftus EV; Colombel JF; Danese S; Rogers R; Bornstein JD; Chen J; Schreiber S; Sands BE; Lirio RA
    Gastroenterology; 2021 Oct; 161(4):1156-1167.e3. PubMed ID: 34144047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease.
    Juncadella A; Papamichael K; Vaughn BP; Cheifetz AS
    Dig Dis Sci; 2018 Nov; 63(11):3067-3073. PubMed ID: 30006816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
    Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
    Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease.
    Kato M; Sugimoto K; Ikeya K; Takano R; Matsuura A; Miyazu T; Ishida N; Tamura S; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Furuta T; Hanai H
    PLoS One; 2021; 16(7):e0254548. PubMed ID: 34242369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.
    Morita Y; Imaeda H; Nishida A; Inatomi O; Bamba S; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
    J Gastroenterol Hepatol; 2016 Nov; 31(11):1831-1836. PubMed ID: 27043158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis.
    Taxonera C; Fernández-Aceñero MJ; Olivares D; Calvo M; Casis B; Bermejo F; López Serrano P; Iborra M; Mesonero F; Boscá Watts M; Díaz Del Arco C; Vera I; Olivares S; Algaba A; Alba C
    Aliment Pharmacol Ther; 2022 Aug; 56(4):614-624. PubMed ID: 35509152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
    Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.
    Little RD; Swaine A; Reynolds R; Gibson DJ; Barrau M; D'Errico F; Hampal R; Sparrow MP; Roblin X; Irving PM; Ward MG
    Inflamm Bowel Dis; 2023 Nov; ():. PubMed ID: 37951220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease.
    Hinojosa J; Muñoz F; Martínez-Romero GJ
    Dig Dis; 2019; 37(6):444-450. PubMed ID: 31039560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A
    Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Ricciuto A; Fish J; Carman N; Walters TD; Church PC; Hansen BE; Crowley E; Siddiqui I; Nguyen GC; Kamath BM; Griffiths AM
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1098-1105.e1. PubMed ID: 29378308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
    Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease.
    Lucafò M; Curci D; Bramuzzo M; Alvisi P; Martelossi S; Silvestri T; Guastalla V; Labriola F; Stocco G; Decorti G
    Front Pediatr; 2021; 9():646671. PubMed ID: 34017806
    [No Abstract]   [Full Text] [Related]  

  • 18. Higher Maintenance Adalimumab Trough Levels are Associated With Achievement of Advanced Remission Targets in Patients With Inflammatory Bowel Disease.
    Ritter E; Hirsch A; Isakov NF; Ron Y; Cohen NA; Maharshak N
    J Clin Gastroenterol; 2021 Oct; 55(9):810-814. PubMed ID: 33060434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
    Brandse JF; Vos LM; Jansen J; Schakel T; Ponsioen CI; van den Brink GR; D'Haens GR; Löwenberg M
    J Crohns Colitis; 2015 Nov; 9(11):973-81. PubMed ID: 26116557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.